ArticleImmunologic research2025
FOXO1 contributes to cigarette smoke condensate-induced cellular senescence and fibrosis in lung fibroblasts through activating the TGF-β1/Smad2/3 signaling pathway.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Extracellular vesicles in senescence-associated chronic lung diseases.Chinese medical journal · 2026Review
- Establishment and characterization of mouse lymph node fibrosis models.Animal models and experimental medicine · 2026Article
- Article
- Review
- Emerging Mechanistic Links Between Fucosylation and Senescence in Lung Diseases.Journal of respiratory biology and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cigarette smoking is the most dominant factor contributing to chronic obstructive pulmonary disease (COPD). Fibroblasts are sensitive to cellular injury induced by cigarette smoke condensate (CSC). This study was devoted to discovering the potential target and exploring its regulatory mechanism in CSC-induced human fibroblasts. Network pharmacological analysis for differential genes in CSC-induced lung fibroblasts MRC5 was performed by a bioinformatics platform. COPD in vitro was induced by CSC in MRC5. The protein expression was analyzed by western blotting. Cellular senescence was tested by senescence-associated β-galactosidase assay and protein detection. Oxidative indexes were examined by corresponding kits. Inflammatory factors were detected using enzyme-linked immunosorbent assay. Markers associated with the TGF-β1/Smad2/3 pathway and fibrosis were also determined via western blotting. FOXO1 and TGF-β1 binding was analyzed by ChIP assay. An animal model was established to explore the effect of FOXO1 in vivo. Gene Ontology (GO) analysis of the differential genes in CSC-induced MRC5 cells indicated gene functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed the top 10 pathways. Forkhead box O 1 (FOXO1) was an upregulated gene in the cellular senescence pathway. Cell function assays suggested that FOXO1 knockdown restrained CSC-induced cellular senescence, oxidative stress, and inflammation in MRC5. FOXO1 downregulation inactivated the TGF-β1/Smad2/3 pathway and suppressed fibrosis markers in CSC-treated MRC5 cells. FOXO1 directly interacted with TGF-β1 promoter and facilitated cell senescence by upregulating TGF-β1. TGF-β1 abolished the suppression of TGF-β1/Smad2/3 pathway and fibrosis caused by FOXO1 knockdown. FOXO1 promoted COPD in mice by regulating the TGF-β1/Smad2/3 pathway. The obtained evidence affirmed that FOXO1 contributed to CSC-induced cellular senescence and fibrosis by promoting TGF-β1 transcription to mediate the TGF-β1/Smad2/3 pathway, indicating an important mechanism in the pathogenesis of COPD.
Indexed as
Identifiers
40498253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.